Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alpharma has signed an agreement under which its sales force will co-promote Synthon's depression, obsessive/compulsive disorder and panic disorder treatment, Pexeva.
Subscribe to our email newsletter
Pexeva is a branded selective serotonin reuptake inhibitor for the treatment of depression, obsessive/compulsive disorder, and/or panic disorder. Pexeva was launched by Synthon in February 2004, and is supported by a specialist sales force focusing on psychiatry.
Alpharma will promote this product along with its current branded product Kadian, a sustained release morphine sulfate product with unique pharmacokinetic properties, which is the only sustained release morphine product approved for both once and twice daily dosing. Since patients experiencing pain often suffer from depression, Kadian and Pexeva are complementary products.
“We believe Pexeva is an excellent companion product to Kadian and we look forward to a successful partnership with Synthon,” said Ron Rocca, vice president of sales and marketing for Alpharma’s branded products. “This agreement supports our branded strategy which is based on a comprehensive view of pain treatment, and we will continue to seek out collaborative partnerships.”
Alpharma does not expect this agreement to have a material impact on its 2005 financial results.